<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958619</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_OZ439_13_004</org_study_id>
    <secondary_id>2013-003409-25</secondary_id>
    <nct_id>NCT01958619</nct_id>
  </id_info>
  <brief_title>Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers</brief_title>
  <official_title>Open Label Pharmacokinetic Study of OZ439 and Piperaquine Following Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in the Fasted State in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Richmond Pharmacology Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A healthy volunteer study to characterise the exposure of the two study medications,
      following administration of OZ439 + TPGS granules with piperaquine phosphate granules
      (intended for children) and with piperaquine phosphate tablets (intended for adults).
      Ideally, to confirm the exposure demonstrated in an earlier bioavailability study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1 open label parallel group, four arm study conducted in healthy male and female
      subject aged 18 to 55 years of age. Subjects will receive either treatment A, B, C or D as
      described below:

        -  Treatment A: 1440 mg PQP tablets and 800 mg OZ439 + TPGS granules for oral suspension

        -  Treatment B: 960 mg PQP tablets and 800 mg OZ439 + TPGS granules for oral suspension

        -  Treatment C: 960 mg PQP granules for oral solution and 800 mg OZ439 + TPGS granules for
           oral suspension

        -  Treatment D: 800 mg OZ439 + TPGS granules for oral suspension
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OZ439 Cmax</measure>
    <time_frame>Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.</time_frame>
    <description>OZ439 observed maximum drug plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OZ439 AUC0-∞</measure>
    <time_frame>Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.</time_frame>
    <description>OZ439 Area under plasma concentration time curve from time zero extrapolated to infinity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Piperaquine Cmax</measure>
    <time_frame>Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.</time_frame>
    <description>Piperaquine Observed maximum drug plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Piperaquine AUC0-∞</measure>
    <time_frame>Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.</time_frame>
    <description>Piperaquine Area under plasma concentration time curve from time zero extrapolated to infinity.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Treatment A: 1440mg PQP tablets &amp; 800mg OZ439 + TPGS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: 960mg PQP tablets &amp; 800mg OZ439 + TPGS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: 960mg PQP granules &amp; 800mg OZ439 + TPGS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: 800mg OZ439 + TPGS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1440mg PQP tablets</intervention_name>
    <description>Piperaquine phosphate tablets (1440mg)</description>
    <arm_group_label>Treatment A: 1440mg PQP tablets &amp; 800mg OZ439 + TPGS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>960mg PQP tablets</intervention_name>
    <description>Piperaquine phosphate tablets (960mg)</description>
    <arm_group_label>Treatment B: 960mg PQP tablets &amp; 800mg OZ439 + TPGS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>800mg OZ439 + TPGS</intervention_name>
    <description>OZ439 (800mg) + TPGS granules for oral suspension</description>
    <arm_group_label>Treatment A: 1440mg PQP tablets &amp; 800mg OZ439 + TPGS</arm_group_label>
    <arm_group_label>Treatment B: 960mg PQP tablets &amp; 800mg OZ439 + TPGS</arm_group_label>
    <arm_group_label>Treatment C: 960mg PQP granules &amp; 800mg OZ439 + TPGS</arm_group_label>
    <arm_group_label>Treatment D: 800mg OZ439 + TPGS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>960mg PQP granules</intervention_name>
    <description>Piperaquine phosphate granules for oral solution (960mg)</description>
    <arm_group_label>Treatment C: 960mg PQP granules &amp; 800mg OZ439 + TPGS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy, male or female, any race aged 18-55 years at screening

          -  body mass index of 18-30kg/m2 inclusive; and a total body weight &gt;50kg and up to 100kg
             at screening

          -  Females must have negative pregnancy test at screening, be non-lactating and of
             non-childbearing potential confirmed by:

               -  natural (spontaneous) post-menopausal defined as amenorrheic for 12 months
                  without an alternative medical cause with a screening FSH level &gt;25IU/L for post
                  menopause

               -  irreversible surgical sterilisation by bilateral oophorectomy or bilateral
                  salpingectomy but not tubal ligation (with or without hysterectomy) at least six
                  months ago

          -  Must agree to use acceptable methods of contraception Males must use acceptable
             methods of contraception if the male subject's partner could become pregnant from the
             time of the first administration of treatment or study medication until 3 months
             following administration of the last dose of study medication

        One of the following acceptable methods of contraception must be used:

          -  Condom &amp; occlusive cap (diaphragm or cervical/vault caps) with spermicidal
             foam/gel/film/cream/suppository)

          -  Surgical sterilisation (vasectomy with documentation of azoospermia) and a barrier
             method (condom or occlusive cap [diaphragm or cervical/vault caps] used with
             spermicidal foam/gel/film/cream/suppository)

          -  Female partner uses oral contraceptives (combination oestrogen/progesterone pills),
             injectable progesterone or subdermal implants and a barrier method (as above)

          -  Female partner uses medically prescribed topically-applied transdermal contraceptive
             patch and a barrier method (as above)

          -  Female partner has had documented tubal ligation (sterilization). In addition, a
             barrier method (as above) must be used

          -  Female partner has had documented placement of an intrauterine device or system and
             the use of a barrier method (as above)

          -  True abstinence: when in line with the preferred and usual lifestyle of the subject.
             Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods)
             and withdrawal are not acceptable methods of contraception. Abstinent subjects must
             agree use one of the above-mentioned contraceptive methods, if sexual relationships
             start during the study or up to 90 days after the last dose of study drug

               -  Subjects should not donate egg and sperm from the time of administration of study
                  medication until 3 months after study medication

               -  Must be capable of understanding and complying with the requirements of the
                  protocol and must have signed the informed consent form prior to undergoing any
                  study-related procedures

        Exclusion Criteria:

          -  Male subjects with female partner(s) who is (are) pregnant or lactating from the time
             of the administration of study medication

          -  Has a clinically significant disease or any condition or disease that might affect
             drug absorption, distribution or excretion

          -  History of allergic reaction to artemisinin-based compounds, 4-aminoquinolines such as
             piperaquine or any other clinically relevant allergy to drugs or food

          -  Any clinically significant abnormal laboratory, vital signs or other safety findings
             as determined by medical history, physical examination or other evaluations conducted
             at screening or on admission

          -  History or current evidence of any clinically relevant cardiovascular, pulmonary,
             hepatic, renal, gastrointestinal (excluding appendectomy and cholecystectomy),
             haematological, endocrinological, immunological, metabolic, neurological, oncological,
             psychiatric, urological or other disease, or current infection

          -  History of post-antibiotic colitis

          -  Electrocardiogram abnormalities in the 12-lead Electrocardiogram (at screening) and/or
             24-hour Holter Electrocardiogram (at screening) which in the opinion of the
             Investigator is clinically relevant or will interfere with the ECG analysis

          -  History of clinically significant Electrocardiogram abnormalities, or any of the
             following abnormalities at screening or on admission:

               -  PR &gt;200ms

               -  QRS complex &gt;120ms

               -  QTcB or QTcF &gt;450ms or shortened QTcB or QTcF less than 340ms for males and
                  females or family history of long QT syndrome or sudden death

               -  Any degree of heart block (such as first, second or third degree atrioventricular
                  block, incomplete, full or intermittent bundle branch block)

               -  Abnormal T wave morphology / prominent U waves

          -  Positive results in any of the serology tests for Hepatitis B Surface Antigen, anti
             Hepatitis core antibody, Hepatitis C antibodies, and HIV 1 and 2 antibodies

          -  Confirmed positive results from urine drug screen (amphetamines, benzodiazepines,
             cocaine, cannabinoids, opiates, barbiturates, and methadone) or from the alcohol
             breath test at screening and admission

          -  History or clinical evidence of alcohol abuse, or any recreational drug abuse within
             the 2 years of screening

          -  Mentally handicapped

          -  Participation in a drug trial within 90 days of drug administration

          -  Use of ANY prescription or over the counter medications, within 3 weeks of study
             medication administration, or vitamins or herbal supplements within 2 weeks of
             administration of the study drug, unless prior approval is granted. Intermittent use
             of paracetamol at doses of up to 2g/day is permitted

          -  Use of moderate/strong inhibitors and/or inducers of CYP450 in 4 weeks of drug
             administration (or at least 5 half-lives of the compound whichever is the longer)

          -  Veins unsuitable for intravenous puncture or cannulation on either arm (veins
             difficult to locate, access or puncture, or veins with a tendency to rupture during or
             after puncture)

          -  Transaminases, bilirubin, serum potassium outside normal range at screening or
             admission

          -  Haemoglobin &lt; lower limit of normal at screening or admission

          -  Donation of &gt;500mL blood in 90 days prior to drug administration

          -  Must be non-smoker for at least three months before screening. &quot;Tobacco use&quot; includes
             smoking and the use of snuff and chewing tobacco, and other nicotine containing
             products. May not use any non-nicotine containing smoking cessation aids, e.g.
             varenicline, for at least three months before screening

          -  Any consumption of grapefruit, Seville oranges, wild grapes, black mulberries,
             pomegranates as fruit juice, marmalade or as a raw fruit within 7 days prior to dosing
             of study drug and throughout the study

          -  Any circumstances or conditions, which may affect full participation in the trial or
             compliance with the protocol

          -  Legal incapacity or limited legal capacity at screening

          -  Vegetarians, vegans or any dietary restrictions conflicting with the study
             standardised menus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Lorch, MD FRCA FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Pharmacology Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richmond Pharmacology Ltd.</name>
      <address>
        <city>Croydon</city>
        <state>London</state>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <results_first_submitted>April 8, 2015</results_first_submitted>
  <results_first_submitted_qc>April 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2015</results_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>open label</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>parallel group</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment A: 1440mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
          <description>Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
        <group group_id="P2">
          <title>Treatment B: 960mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
          <description>Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
        <group group_id="P3">
          <title>Treatment C: 960mg PQP Granules &amp; 800mg OZ439 + TPGS</title>
          <description>Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
        <group group_id="P4">
          <title>Treatment D: 800mg OZ439 + TPGS</title>
          <description>OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who received at least one single dose of OZ439 or Piperaquine</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment A: 1440mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
          <description>Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
        <group group_id="B2">
          <title>Treatment B: 960mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
          <description>Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
        <group group_id="B3">
          <title>Treatment C: 960mg PQP Granules &amp; 800mg OZ439 + TPGS</title>
          <description>Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
        <group group_id="B4">
          <title>Treatment D: 800mg OZ439 + TPGS</title>
          <description>OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="9.40"/>
                    <measurement group_id="B2" value="31.8" spread="9.70"/>
                    <measurement group_id="B3" value="26.9" spread="5.66"/>
                    <measurement group_id="B4" value="28.6" spread="9.54"/>
                    <measurement group_id="B5" value="28.5" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>OZ439 Cmax</title>
        <description>OZ439 observed maximum drug plasma concentration</description>
        <time_frame>Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: 1440mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: 960mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: 960mg PQP Granules &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: 800mg OZ439 + TPGS</title>
            <description>OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 Cmax</title>
          <description>OZ439 observed maximum drug plasma concentration</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1300" spread="34.6"/>
                    <measurement group_id="O2" value="1490" spread="37.9"/>
                    <measurement group_id="O3" value="1240" spread="29.2"/>
                    <measurement group_id="O4" value="1120" spread="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OZ439 AUC0-∞</title>
        <description>OZ439 Area under plasma concentration time curve from time zero extrapolated to infinity.</description>
        <time_frame>Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: 1440mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: 960mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: 960mg PQP Granules &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: 800mg OZ439 + TPGS</title>
            <description>OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 AUC0-∞</title>
          <description>OZ439 Area under plasma concentration time curve from time zero extrapolated to infinity.</description>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15000" spread="26.3"/>
                    <measurement group_id="O2" value="16100" spread="35.7"/>
                    <measurement group_id="O3" value="14100" spread="35.9"/>
                    <measurement group_id="O4" value="13400" spread="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Piperaquine Cmax</title>
        <description>Piperaquine Observed maximum drug plasma concentration</description>
        <time_frame>Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: 1440mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: 960mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: 960mg PQP Granules &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine Cmax</title>
          <description>Piperaquine Observed maximum drug plasma concentration</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249" spread="94.3"/>
                    <measurement group_id="O2" value="113" spread="100.9"/>
                    <measurement group_id="O3" value="112" spread="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Piperaquine AUC0-∞</title>
        <description>Piperaquine Area under plasma concentration time curve from time zero extrapolated to infinity.</description>
        <time_frame>Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: 1440mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: 960mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: 960mg PQP Granules &amp; 800mg OZ439 + TPGS</title>
            <description>Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine AUC0-∞</title>
          <description>Piperaquine Area under plasma concentration time curve from time zero extrapolated to infinity.</description>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18300" spread="39.3"/>
                    <measurement group_id="O2" value="12400" spread="43.2"/>
                    <measurement group_id="O3" value="12100" spread="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 50 post-dose.</time_frame>
      <desc>All 55 subjects received one dose of OZ439 alone or in combination with PQP were included in the safety analysis population</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: 1440mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
          <description>Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: 960mg PQP Tablets &amp; 800mg OZ439 + TPGS</title>
          <description>Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
        <group group_id="E3">
          <title>Treatment C: 960mg PQP Granules &amp; 800mg OZ439 + TPGS</title>
          <description>Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
        <group group_id="E4">
          <title>Treatment D: 800mg OZ439 + TPGS</title>
          <description>OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After completion of the study, the Investigator may prepare a joint publication with MMV. The Investigator must undertake not to submit any part of the individual data from this protocol for publication without prior consent of MMV at a mutually agreed time. The confidentiality obligation applies to all personnel involved at the investigational site.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Thomas Rueckle PhD</name_or_title>
      <organization>Medicines for Malaria Venture (MMV)</organization>
      <phone>+41 22 799 4567</phone>
      <email>ruecklet@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

